miRNA在宫颈癌早期诊断及预后中的研究进展  

Advances on miRNA in early diagnosis and prognosis of cervical cancer

作　　者：熊焱强[1,2] 刘朝奇[2] 李志英[1] 

机构地区：[1]三峡大学仁和医院,湖北宜昌443002 [2]三峡大学分子生物学研究所,湖北宜昌443002

出　　处：《基础医学与临床》2015年第6期842-845,共4页Basic and Clinical Medicine

基　　金：湖北省教育厅自然科学研究重点项目(D20121308)

摘　　要：微小RNA(miRNA)在宫颈癌的发生、侵袭、转移和复发等过程中扮演重要角色,与其预后密切相关。宫颈癌患者血清中异常表达的miRNA可作为其无创诊断和预后判断的生物标志物,通过研究血清miRNA可以早期诊断宫颈癌,减少肿瘤的转移和复发,寻找治疗靶点,为宫颈癌的诊疗提供突破点。MicroRNA plays an important role in the process of cervical cancer incidence,invasion,metastasis and recurrence,and closely related to the prognosis.The abnormal expression of miRNAs in serum of cervical cancer patients can be used as a noninvasive diagnostic and prognostic biomarkers.Based on studies of serum microRNAs,the early phase of cervical cancer can be found,and thus reduce tumor metastasis and recurrence,search for therapeutic targets,tumor recurrence are reduced,and find targets and breakthrough in diagnosis and treatment of cervical cancer.

关 键 词：宫颈癌 微小RNA 早期诊断 预后 

分 类 号：R737.33[医药卫生—肿瘤]